The central target of $36 is the arithmetic mean of roughly ten current, individually verified analyst price targets, which span a wide $27 to $47 range. At a recent price near $28 following third-quarter 2026 results, reaching $36 would require a gain of roughly 28% — a substantial, though not extraordinary, move.
ENOV jumped from a previous close of $24.42 to $27.56, up +12.86%, during regular market hours on November 5. The catalyst was Q3 2026 earnings: adjusted EPS of $0.88 beat the ~$0.77 consensus, full-year EPS guidance was raised, and a new $200 million buyback was authorized.
Accuray (ARAY) fell from a $0.1491 prior close to about $0.1131, down -24.15%, with selling running from premarket into the regular session. After the November 4 close, Accuray reported weaker Q1 FY2027 results—revenue of $86.5M missed estimates and product revenue fell 26%—and announced a 1-for-40 reverse stock split effective November 9 to restore Nasdaq's $1.00 minimum bid price.
TRIB shares dropped to $5.00 from a prior close of $6.30, a decline of -20.63%, during regular trading hours. No verified news or fundamental catalyst found. The move is likely driven by thin liquidity in this micro-cap and a continuation of its multi-month downtrend — its typical daily move is roughly ±4.5%, making today's swing about 4.6x normal.
Adagio Medical Holdings (ADGM) fell -30.16% during Thursday's regular session, sliding from a prior close of $0.0862 to $0.0602. The drop followed the company's Nov. 4 filing to execute a 1-for-30 reverse stock split, effective Nov. 6, to regain Nasdaq listing compliance—a step typically read as bearish for a distressed micro-cap.
SNWV plummeted during regular market hours, tumbling from a prior close of $5.73 to roughly $2.40, a -58.12% single-session decline. No verified news or fundamental catalyst found. The move is consistent with thin order-book selling in a speculative micro-cap that routinely swings several percent, and occasionally double digits, per session.
Accuray reported first quarter fiscal 2027 net revenue of $86.5 million , down 8% year over year, as product revenue continued to face pressure. Service revenue rose 4% to $59.2 million , supported by a growing installed base and pricing actions.
electroCore reported third quarter 2026 net sales of approximately $9.7 million, up about 12% year over year, though below the roughly $10.9 million consensus revenue estimate. Net loss narrowed to $1.3 million, or $0.13 per share, from $3.4 million, or $0.40 per share, a year earlier — beating the consensus estimate of a $0.26 per-share loss.
Total revenue rose about 14% year over year to $33.6 million, with product revenue up 15% to $23.7 million. Recurring revenue (consumables plus service) increased 10% to $23.1 million, underscoring a stable, predictable base.
Total revenue rose 12.5% year over year to $41.96 million, ahead of consensus estimates near $40.9 million. Net loss narrowed sharply to $1.7 million, or $0.02 per share, from $9.0 million, or $0.13 per share, in the prior-year quarter.
Wall Street expects Viemed Healthcare to report earnings of $0.12 per share on revenue of roughly $80.78 million for the third quarter of 2026. The consensus figures imply earnings-per-share (EPS) growth of about 33% and revenue growth of about 12% versus the same quarter a year earlier.
Sight Sciences reported record total revenue of $24.9 million for the third quarter of 2026, up 25% year over year from $19.9 million. Interventional Glaucoma (IG) revenue grew 7% to $21.0 million, while Interventional Dry Eye (IDE) revenue hit a record $3.9 million , up 45% sequentially.
Cytek Biosciences reported third-quarter 2026 revenue of $53.2 million , up 2% year over year and slightly above the consensus estimate of roughly $53.0 million. GAAP (Generally Accepted Accounting Principles) earnings per share came in at a loss of $0.05 , narrower than the analyst estimate of a $0.06 loss.
Pacific Biosciences (PacBio) reported third-quarter 2026 total revenue of $40.56 million , up 5.5% year over year and above analyst consensus estimates of roughly $39.3 million. Non-GAAP net loss per share came in at -$0.11 , beating the consensus estimate of -$0.13 per share, while GAAP net loss narrowed to -$0.12 per share.
PROCEPT BioRobotics reported third-quarter 2026 revenue of $98.3 million , up 18% year over year, but slightly below the consensus estimate of roughly $100.5 million. Net loss per share (EPS, or earnings per share) was $0.46 , a larger loss than the $0.39 analysts had expected.
LivaNova reported third-quarter 2026 net revenue of $393.1 million , up 9.9% year over year and ahead of the roughly $381 million consensus estimate. Adjusted diluted earnings per share (EPS) came in at $1.23 , up from $1.11 a year earlier and above the approximately $1.06 analyst consensus.
Bruker reported third quarter 2026 revenue of $874.0 million , up 1.6% year over year, with organic growth of 0.7%. Non-GAAP (adjusted) diluted earnings per share (EPS) reached $0.56 , up 24.4% from $0.45 a year earlier and well above the roughly $0.42 consensus estimate.
Bio-Rad Laboratories reported third-quarter 2026 net sales of approximately $656.4 million , up 0.5% year over year and slightly above the consensus estimate of $649.95 million. Non-GAAP diluted earnings per share (EPS) came in at $2.65 , up from $2.26 a year earlier and ahead of the roughly $2.23 consensus estimate.
Insulet reported third-quarter 2026 revenue of $842 million , up 19.2% year over year, edging above the roughly $833 million consensus estimate. Adjusted earnings per share came in at $1.99 , well ahead of the $1.59 analyst consensus and up 27.5% from the prior-year period.
Smith & Nephew reported third quarter 2026 revenue of $1.551 billion, up 3.4% year over year on both a reported and underlying basis, an acceleration from the second quarter. Management lowered full-year 2026 guidance, now expecting underlying revenue growth of around 3% (previously around 4%) and trading profit of roughly $1.25 billion (previously around $1.3 billion).